The issue with an "evidence-based" approach is that conducting studies to generate evidence requires substantial capital, and that capital is most available for

The issue with an "evidence-based" approach is that conducting studies to generate evidence requires substantial capital, and that capital is most available for treatments that are supported by major companies. In this case, pharmaceutical companies make substantial profits from selling stimulants, and medical insurers favour CBT for a variety of reasons, including relatively short treatment timelines. Consequently, evidence will be biased towards those therapies, so the volume of evidence isn't really a good basis for comparing different treatments.